Highlights in skin cancer at ESMO 2022

Dirk Schadendorf, MD, University Hospital Essen, Essen, Germany, comments on important trials in the field of skin cancer presented at the European Society for Medical Oncology (ESMO) 2022 Congress, including results of the Phase II IMMUNED trial (NCT02523313) of adjuvant nivolumab alone or in combination with ipilimumab versus placebo in stage IV melanoma. Prof. Schadendorf additionally highlights novel trials investigating treatments for Merkel cell carcinoma. This interview took place at the ESMO 2022 Congress in Paris, France.